



**Welcome to the ARTnet newsletter in which we highlight latest progress and outline our planned future activities.**

### **Scientific Committee Update**

The Scientific Committee of ARTnet has continued to meet quarterly over 2015/2016 by teleconference and will meet in person at the ANZSNM ASM in Rotorua 2016. The Committee has made significant progress this year, in particular with PSMA PET initiatives, and with the development of the ARTnet site initiation program. More details are provided below.

### **PSMA PET clinical trials – update**

- **PCFA Movember Clinical Trial Award application**

ARTnet is pleased to announce PCFA/Movember clinical trials award **success!!**

**Project title:** 'A prospective multicentre study of the impact of Ga-68 PSMA-PET/CT imaging in the management of prostate cancer (proPSMA study)'

**Principal Investigator:** A/Prof Michael Hofman (Peter Mac, Melbourne)

This exciting project was one of only a limited number of proposals invited to submit a full application for the PCFA/Movember Clinical Trial Award.

A multidisciplinary group of experts from 6 sites have agreed to participate as Co-Principal Investigators and Co-Investigators of this project.

Groups who have supported collaboration in this clinical trial are:

- ARTnet
- TROG
- ANZUP
- USANZ
- Centre for Health Economics Research and Evaluation (CHERE), University of Technology Sydney

Many congratulations to A/Prof Michael Hofman and all of the team for their outstanding achievement and we look forward to reporting on the progress of this important study.

- **Ga68 PSMA PET Management Impact Study**

Recruitment is progressing well to the ARTnet Ga68 PSMA PET Management Impact Study, which is lead by A/Prof Paul Roach and supported by the Garvan Foundation. This study is currently being conducted at 3 sites across Australia.

A trial update will be provided at the ARTnet session at Rotorua.

- **Ga68 PSMA PET Survey**

A survey of Ga68 PSMA has recently been sent to all PET sites in Australia. This survey aims to ascertain current utilisation of PSMA PET in Australia, review imaging protocols, assess capabilities for clinical trials with PSMA PET and in a small subsection of sites, to collect information on radiopharmaceutical synthesis and QC procedures.

The survey will be open until **April 6, 2016**, and the results will be presented at Rotorua.

If you have not received a survey then please contact ARTnet ([scientific.chair@ARTnet.org.au](mailto:scientific.chair@ARTnet.org.au)).

ARTnet is keen for all PET sites in Australia to be involved in the survey, and will plan a follow-up survey in 6 months.

### **Australian Clinical Trials Alliance (ACTA) involvement**

- **Associate Membership**

ARTnet has been accepted as an Associate Member of ACTA, whose mission is to help advance the role and value of investigator-initiated clinical trials and registries in Australia. As an Associate member ARTnet is represented on the ACTA Advisory Council. Prof Andrew Scott is the ARTnet representative for ACTA.

- **ACTA International Clinical Trials Symposium**

Olga Kovacev, ARTnet Project Officer attended the ACTA International Clinical Trials Symposium in Sydney in October 2015. The event had 300-400 attendees, mainly from research sites and networks with excellent presentations from national and international key opinion leaders.

- **Report on the Activities & Achievements of Clinical Trials Networks in Australia 2004 – 2014**

A new report on the activities and achievements of Clinical Trials Networks in Australia has been officially published. The report was commissioned by the National Health and Medical Research Council (NHMRC) and undertaken by ACTA to provide the first detailed snapshot of clinical trials network activity in Australia. ARTnet was one of the participating networks.

For a copy of the report refer to the ACTA website under Publications:  
<http://www.clinicaltrialsalliance.org.au>

### **ARTnet Site Initiation Program**

The ARTnet site initiation program will be officially launched at ANZSNM ASM 2016. This program will utilise the ARTnet phantom to document PET or SPECT camera performance for clinical trials.

The ARTnet phantom assessment can be used for either:

- (i) a 'general' assessment of an imaging device (SPECT or PET camera) to document basic performance under standard conditions, not attached to any particular trial, or
- (ii) a 'specific' assessment designed to determine the suitability of imaging equipment for an individual clinical trial.

The general assessment might be performed to validate a site as a potential partner in future, unspecified clinical imaging trials, whereas the specific assessment would focus on the defined needs of a particular clinical imaging trial in question.

Further details on the process will be outlined on the ARTnet website in April 2016.

### **SIRTEX QUEST study initiative**

ARTnet is currently seeking to identify sites that may be suitable for participation in a SIRTEX QUEST study initiative. To be involved in the study, the site would need to have access to time of flight PET-CT imaging and have experience with Y-90 SIRT therapy.

For further information please register your interest with ARTnet ([scientific.chair@artnet.org.au](mailto:scientific.chair@artnet.org.au)).

### **ANZSNM ASM Rotorua ARTnet session**

Please join us at the ARTnet session of ANZSNM ASM Rotorua, where further updates will be given on all of these initiatives. The ARTnet session is scheduled for **3.45pm on Sunday 24<sup>th</sup> April 2016**.

Please make contact if you would like more information on ARTnet or have any projects or ideas you would like to discuss.

We look forward to keeping you updated with our progress.

Roslyn Francis (on behalf of ARTnet)  
Scientific Chair  
[scientific.chair@ARTnet.org.au](mailto:scientific.chair@ARTnet.org.au)

### **ARTnet Mission Statement**

To promote and facilitate innovative collaborative clinical research utilising radiopharmaceuticals for imaging or therapy.

### **Vision**

- to develop a network of radiopharmaceutical imaging and therapy sites in Australasia with validated capabilities;
- to harmonise imaging protocols for research;
- to facilitate linkages with other clinical trials networks, the pharma industry and funding agencies for multicentre clinical trials;
- to support multicentre clinical trials with radiopharmaceuticals for imaging or therapy, including facilitating data collection, analysis and data management;
- to promote collaboration in clinical trials and outcome-based research with radiopharmaceuticals

[www.ARTnet.org.au](http://www.ARTnet.org.au)

*The Australasian Radiopharmaceutical Trials Network is a collaboration of the*

**Australasian Association of Nuclear Medicine  
Specialists (AANMS)**  
PO Box 73 Balmain NSW 2041 | T +61.2.98184824 |  
F +61.2.9818 4806  
E [research@aanms.org.au](mailto:research@aanms.org.au)

*and  
the*

**Australian and New Zealand Society of Nuclear  
Medicine (ANZSNM)**  
PO Box 2195, Wellington Point, QLD 4160|  
T +61 1300 330 402 | F+61.3.8677 2970  
E [secretariat@anzsnm.org.au](mailto:secretariat@anzsnm.org.au)